ERBB3 and breast cancer: Our studies have demonstrated that crosslinking significantly enhances the endocytosis of Tz in HER2-overexpressing breast cancer and induces effects of potential therapeutic benefit including promotion of HER2 and HER3 downregulation and alteration of HER2 activation and signalling.